Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorder with estimated prevalence in general population of 10-15% in many countries of the world.1 In Pakistan, IBS has been found to be associated with anxiety and depression in 80% of the patients, especially in health care professionals.2 Many pharmacological therapies have been used and have included fiber rich diets, spasmolytic drugs and anti depressants for the treatment of this condition. The knowledge of motor and sensory responses to different stimuli in IBS patients in the pathways to the central nervous system is an important source of information for development of new molecules in this disorder.3 Although, herbal medicines of many varieties4 have been used, recently, tremendous progress in our understanding of this truly global disease has occurred.5 This has lead to the development of new agents targeted at various receptors in the enteric nervous system.6 Several studies from around the world3 have shown that tegaserod, a 5HT4 agonist, has been an effective agent in constipation-dominant IBS (IBS-C).
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
